Treatment of steroid-resistant acute liver transplant rejection with basiliximab.
Current rescue therapies for acute steroid-resistant rejection, such as OKT3 and high-dose tacrolimus, are not uncommonly associated with side effects that contribute to significant morbidity of the patient. Basiliximab is a chimeric monoclonal antibody that acts as an interleukin-2 receptor antagonist on the surface of activated T lymphocytes. It has until now only been used as immunoprophylaxis in adult liver transplant patients. In this report, we describe the use of Basiliximab as rescue therapy in a case of acute steroid-resistant rejection in an adult living related liver transplant recipient.
Fernandes
M L
ML
Liver Transplant Unit, National University Hospital, 5 Lower Kent Ridge Road, Singapore 119074. m9446253lf@yahoo.com
Lee
Y M
YM
Sutedja
D
D
Wai
C T
CT
Isacc
J
J
Prabhakaran
K
K
Lim
S G
SG
Lee
K H
KH
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000077552:Basiliximab; D005260:Female; D006084:Graft Rejection / Q000188:drug therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008111:Liver Function Tests; D016031:Liver Transplantation / Q000276:immunology*; D008875:Middle Aged; D011184:Postoperative Period; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use*
D000305:Adrenal Cortex Hormones; D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D011993:Recombinant Fusion Proteins; D000077552:Basiliximab